Unless otherwise stated, all references are to the Abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (47th ICAAC).

Please note that the material published here by HIV and Hepatitis.com about the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy is not approved by nor is it a part of ICAAC or the American Society of Microbiology.


HIV and AIDS
•Library of Slides and Posters
•Monoclonal Antibody CCR5 Inhibitor PRO 140 Produces Long-lasting HIV Suppression in Single-dose Study
•Interrupting Antiretroviral Therapy Does Not Lower the Risk of Cardiovascular Disease in People with HIV
•Switching to Nevirapine (Viramune) Appears Generally Safe for Patients with High CD4 Cell Counts
•Ritonavir-boosted Elvitegravir Has Potent and Durable Activity in Treatment-experienced Patients with Active Optimized Background Therapy
•Individuals with the HLA-B*5701 Genetic Variation Have More Abacavir Hypersensitivity Symptoms
•Lack of Clinically Relevant Drug Interactions Between Ritonavir-boosted Elvitegravir and Experimental NNRTI Etravirine (TMC125)
•Once-daily Efavirenz 600 mg Has No Clinically Relevant Effect on the Pharmacokinetics of Tipranavir or Ritonavir in Healthy Volunteers
•Raltegravir (Isentress) Demonstrates Sustained Viral Suppression through 48 Weeks in Treatment-experienced Patients
•Promising New Longer-term Data on Pfizer's CCR5 Antagonist Maraviroc (Selzentry)
•Patients with CXCR4-tropic or Dual/mixed-tropic HIV Experience Earlier Treatment Failure on Maraviroc than Those with CCR5-tropic Virus
•Trofile Assay Accurately Determines HIV Co-receptor Tropism and Identifies Patients Who Can Use CCR5 Antagonist Maraviroc
•

Phase 3 Study Data on Once-daily Darunavir/ritonavir (Prezista) Versus Lopinavir/ritonavir (Kaletra) in Treatment-naïve HIV Patients: The ARTEMIS Trial

•CD4 Lymphocyte and Leukocyte Response to Vicriviroc (VCV) in 282 HIV-Infected Treatment-naive and Experienced Subjects: Pooled Data from 4 Randomized Clinical Trials
•
Two-Year Follow-up of Treatment-experienced Patients on Vicriviroc (VCV)
•
Baseline Darunavir Sensitivity Does Not Predict Response to Boosted Ritonavir plus Enfuvirtide in Triple-class-experienced Patients: BLQ Study Final Results
Hepatitis C
•Interim Efficacy and Resistance Data from a Phase II Study of Telaprevir (VX-950) Plus Pegylated Interferon and Ribavirin in Previously Untreated Patients with Hepatitis C
•
Patients with Depression prior to Hepatitis C Treatment Are Half as Likely to Achieve Sustained Virological Response
HIV-HCV Coinfection
•
HAART -- Especially Nevirapine -- May Slow Progression of Liver Fibrosis in HIV-HCV Coinfected Individuals
•Rapid HCV Clearance after 4 Weeks on Pegylated Interferon Plus Ribavirin Is the Best Predictor of Sustained Virological Response
 Predictors of Advanced Liver Fibrosis in an Urban Cohort of HIV-HCV Coinfected Patients
•Pegasys Versus PegIntron for Combination Hepatitis C Treatment of HIV-HCV Coinfected Patients
•Profile of Patients Triply Infected with HIV, HBV, and HCV in the HAART Era
•
HCV and HIV Infection Stimulate Distinct Immune Response Patterns